靶向治疗时代及以后减瘤性肾切除术作用的系统综述:转移性肾细胞癌的个体化方法
该系统综述评估靶向治疗时代减瘤性肾切除术(CN)对转移性肾细胞癌(mRCC)总生存(OS)的影响及其相关因素。纳入63篇报告(56项研究),多数非随机研究显示CN与OS改善相关,但一项随机试验(CARMENA)发现单用舒尼替尼的OS不劣于CN后舒尼替尼。结论认为需系统治疗者应优先系统治疗,CN对转移负荷有限、特定预后因素良好或系统治疗后反应良好者仍可能有益。
要点
- 需药物治疗的初诊mRCC患者应优先系统治疗,CN仅适用于选择性人群。
- CN与OS改善的关联主要来自非随机研究,随机证据(CARMENA)未显示CN优势。
- CN围手术期死亡风险0%–10.4%,Clavien≥3并发症3%–29.4%。
核心结论
- 目前对需要药物治疗的初诊mRCC患者应优先系统治疗,CN在转移负荷有限、可监测或转移灶切除、系统治疗后反应良好或需症状缓解的患者中仍可能发挥作用。
研究设计与样本
- 检索Medline、EMBASE和Cochrane数据库(建库至2018年6月4日)的英文临床试验、队列研究和病例对照研究,评估接受与未接受CN的mRCC患者,主要结局为OS,共纳入63篇报告(56项研究)。
主要发现
- 10项非随机研究显示CN与mRCC患者OS改善相关。
- 一项随机试验(CARMENA)发现单用舒尼替尼的OS不劣于CN后舒尼替尼。
- CN围手术期死亡风险范围为0%–10.4%,Clavien≥3并发症风险范围为3%–29.4%, upfront CN与术前系统治疗后CN之间无有意义差异。
- CN后12.9%–30.4%的患者未接受系统治疗。
- 术前系统治疗进展、高C反应蛋白、高中性粒细胞-淋巴细胞比值、IMDC/MSKCC风险分类差、肉瘤样去分化和体能状态差是最一致的OS降低预后因素;体能状态好和IMDC/MSKCC风险分类好/中是最一致的CN OS获益预测因素。
临床怎么用
- 对需要药物治疗的初诊mRCC患者,应优先启动系统治疗。
- CN可考虑用于转移负荷有限、适合监测或转移灶切除的患者,或初始系统治疗后反应良好的患者,或用于症状缓解。
局限性
- 50项研究偏倚风险为中等或严重。
- 多数支持CN与OS改善相关的证据来自非随机研究。
- SURTIME研究效能不足,结果仅为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The role of cytoreductive nephrectomy (CN) in the management of metastatic renal cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. OBJECTIVE: To assess if CN versus no CN is associated with improved overall survival (OS) in patients with mRCC treated in the TT era and beyond, characterize the morbidity of CN, identify prognostic and predictive factors, and evaluate outcomes following treatment sequencing. EVIDENCE ACQUISITION: Medline, EMBASE, and Cochrane databases were searched from inception to June 4, 2018 for English-language clinical trials, cohort studies, and case-control studies evaluating patients with mRCC who underwent and those who did not undergo CN. The primary outcome was OS. Risk of bias was evaluated using the Cochrane Collaborative tools. EVIDENCE SYNTHESIS: We identified 63 reports on 56 studies. Risk of bias was considered moderate or serious for 50 studies. CN was associated with improved OS among patients with mRCC in 10 nonrandomized studies, while one randomized trial (CARMENA) found that OS with sunitinib alone was noninferior to that with CN followed by sunitinib. The risk of perioperative mortality and Clavien ≥3 complications ranged from 0% to 10.4% and from 3% to 29.4%, respectively, with no meaningful differences between upfront CN or CN after presurgical systemic therapy (ST). Notably, 12.9-30.4% of patients did not receive ST after CN. Factors most consistently prognostic of decreased OS were progression on presurgical ST, high C-reactive protein, high neutrophil-lymphocyte ratio, poor International Metastatic renal cell carcinoma Database Consortium (IMDC)/Memorial Sloan Kettering Cancer Center (MSKCC) risk classification, sarcomatoid dedifferentiation, and poor performance status. At the same time, good performance status and good/intermediate IMDC/MSKCC risk classification were most consistently predictive of OS benefit with CN. In a randomized trial investigating the sequence of CN and ST (SURTIME), an OS trend was observed with CN after a period of ST in patients without progression compared with upfront CN. However, the study was underpowered and results are exploratory. CONCLUSIONS: Currently, ST should be prioritized in the management of patients with de novo mRCC who require medical therapy. CN maintains a role in patients with limited metastatic burden amenable to surveillance or metastasectomy, and may potentially be considered in patients with favorable response after initial ST or for symptom's palliation. PATIENT SUMMARY: In the contemporary era, receiving systemic therapy is the priority in metastatic kidney cancer. Nephrectomy still has a role in patients with limited burden of metastases, well-selected patients based on established prognostic and predictive factors, and patients with a favorable response after initial systemic therapy.
引用
- Bhindi B, Abel EJ, Albiges L, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2018. PMID: 30467042. doi:10.1016/j.eururo.2018.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。